Skip to main content
Log in

Comparison of the Anticonvulsant Activities of Substituted Hydroxycoumarins and 4-[(3-Nitro-2-Oxo-2H-Chromen-4-Yl)Amino]Butanoic Acid

  • Published:
Pharmaceutical Chemistry Journal Aims and scope

The anticonvulsant activity of hydroxycoumarin derivatives and 4-[(3-nitro-2-oxo-2H-chromen-4-yl)amino] butanoic acid was studied using nicotine and corazole convulsion models. All investigated compounds protected animals from death in 100% of cases after intraperitoneal administration of the LD50 of nicotine (14 mg/kg). 4-[(3-Nitro-2-oxo-2H-chromen-4-yl)amino]butanoic acid showed anticonvulsant activity at a dose of 20 mg/kg in the corazole convulsion test while 7-(2-morpholino-2-oxoethoxy)-2H-chromen-2-one (a 7-hydroxycoumarin derivative) prevented convulsions at a dose of 200 mg/kg, which was comparable to the anticonvulsant effect of valproic acid at the same dose. An analysis of the results suggested different mechanisms for the anticonvulsant action of the investigated substances, which was indicative of good prospects for further development of coumarin derivatives as agents with wide spectra of anticonvulsant activity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2.
Fig. 3.
Fig. 4.

Similar content being viewed by others

References

  1. E. V. Parfenova, F. K. Rider, A. G. Gersamiya, et al., Zh. Nevrol. Psikhiatr., 118(9), 77 – 85 (2018).

    Article  CAS  Google Scholar 

  2. T. L. Mac, D. S. Tran, F. Quet, et al., Lancet Neurol., 6(6), 533 – 543 (2007).

    Article  Google Scholar 

  3. T. R. Browne and G. L. Holmes, Handbook of Epilepsy, Lippincott Williams & Wilkins, Philadelphia (2004) [Russian translation, Binom, Moscow (2006)].

  4. S. A. Gromov, N. A. Sivakova, E. A. Korsakova, et al., Obozr. Psikhiatr. Med. Psikhol., No. 3, 34 – 40 (2017).

  5. S. A. Gromov and N. G. Naznanov (eds.), Epilepsy [in Russian], St. Petersburg (2015), pp. 839 – 857.

  6. S. A. Gromov and N. G. Neznanov (eds.), Epilepsy [in Russian], St. Petersburg (2015), pp. 857 – 891.

  7. P. D. Shabanov, Psychopharmacology [in Russian], N-L, St. Petersburg (2008).

  8. D. J. Chong and A. M. Lerman, Curr. Neurol. Neurosci. Rep., 16(4), 39 – 42 (2016).

    Article  CAS  Google Scholar 

  9. O. A. Pylaeva, K. Yu. Mukhin, and A. S. Petrukhin, Side Effects of Antiepileptic Therapy [in Russian], Vol. 236, Granat, Moscow (2016).

    Google Scholar 

  10. P. N. Patsalos, D. J. Berry, B. F. D. Bourgeois, et al., Epilepsia, 49(7), 1239 – 1276 (2008).

    Article  CAS  Google Scholar 

  11. P. P. Denisenko and A. A. Tarasenko, RU Pat. 2,452,732, Jun. 10, 2012; Izobret. Polezn. Modeli, No. 16, 2012).

  12. J. Bryda, M. Zagaja, A. Szewczyk, et al., Acta Neurobiol. Exp., 79, 126 – 132 (2019).

    Google Scholar 

  13. L. W. Hazleton, T. W. Tusing, B. R. Zeitlin, et al., J. Pharmacol. Exp. Ther., 118(3), 348 – 358 (1956).

    PubMed  CAS  Google Scholar 

  14. M. L. Zinovieva and P. G. Zhminko, J. Pharm. Pharmacol., 5, 237 – 244 (2017).

    Google Scholar 

  15. M. O. Karatas, H. Uslu, S. Sari, et al., J. Enzyme Inhib., 31(5), 760 – 772 (2016).

    Article  CAS  Google Scholar 

  16. M. Mohammadi-Khanaposhtani, N. Ahangar, S. Sobhani, et al., Bioorg. Chem., 89, 102989 – 102993 (2019).

    Article  CAS  Google Scholar 

  17. A. P. Kourounakis, D. Xanthopoulos, and A. Tzara, Med. Res. Rev., 1 – 44 (2019).

  18. P. D. Shabanov, L. V. Myznikov, et al., RU Pat. 2,655,929, May 30, 2018; Izobret. Polezn. Modeli, No. 16 (2018).

  19. P. D. Shabanov, L. V. Myznikov, et al., RU Pat. 2,705,810, Nov. 12, 2019; Izobret. Polezn. Modeli, No. 32 (2019).

  20. G. V. Mokrov, S. A. Litvinova, T. A. Voronina, et al., Med. Chem. Res., 28(11), 1901 – 1911 (2019).

    CAS  Google Scholar 

  21. V. P. Fisenko, Handbook of Experimental (Preclinical) Study of New Pharmacological Substances [in Russian], Remedium, Moscow (2000).

    Google Scholar 

  22. T. A. Voronina, L. N. Nerobokova, and A. N. Mironov (eds.), Handbook for Preclinical Drug Trials [in Russian], Part 1, Grif i K, Moscow (2012), pp. 235 – 250.

  23. W. Loschere, D. Honack, C. P. Fassbendeer, et al., Epilepsy Res., 8(2), 171 – 189 (1991).

    Article  Google Scholar 

  24. M. V. Veselovskaya, S. V. Shilin, and V. P. Khilya, Chem. Nat. Compd., 48(5), 757 – 760 (2012).

    Article  CAS  Google Scholar 

  25. B. S. Diwakar, B. Govindh, Y. N. Sastry, et al., Med. Chem. Res., 24(4), 1546 – 1557 (2015).

    CAS  Google Scholar 

  26. R. U. Khabriev, Handbook of Experimental (Preclinical) Study of New Pharmacological Substances [in Russian], Meditsina, Moscow (2000).

    Google Scholar 

  27. A. N. Mironov, N. D. Bunyatyan, A. N. Vasil’ev, et al., Handbook for Preclinical Drug Trials [in Russian], Part 1, Grif i K, Moscow (2012).

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to E. E. Yakovleva.

Additional information

Translated from Khimiko-Farmatsevticheskii Zhurnal, Vol. 54, No. 9, pp. 22 – 26, September, 2020.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yakovleva, E.E., Myznikov, L.V. & Shabanov, P.D. Comparison of the Anticonvulsant Activities of Substituted Hydroxycoumarins and 4-[(3-Nitro-2-Oxo-2H-Chromen-4-Yl)Amino]Butanoic Acid. Pharm Chem J 54, 904–908 (2020). https://doi.org/10.1007/s11094-020-02294-9

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11094-020-02294-9

Keywords

Navigation